{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:30:36Z","timestamp":1794706236241,"version":"4.9.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41574-026-01252-x","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:36:38Z","timestamp":1776684998000},"page":"452-462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pathophysiology, diagnosis and management of secondary osteoporosis"],"prefix":"10.1038","volume":"22","author":[{"given":"Julien","family":"Paccou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-1906","authenticated-orcid":false,"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem F.","family":"Lems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Compston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"1252_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston, J. E., McClung, M. R. & Leslie, W. D. Osteoporosis. Lancet 393, 364\u2013376 (2019).","journal-title":"Lancet"},{"key":"1252_CR2","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.jocd.2023.101435","volume":"27","author":"C Shuhart","year":"2024","unstructured":"Shuhart, C. et al. Executive summary of the 2023 Adult Position Development Conference of the International Society for Clinical Densitometry: DXA reporting, follow-up BMD testing and trabecular bone score application and reporting. J. Clin. Densitom. 27, 101435 (2024).","journal-title":"J. Clin. Densitom."},{"key":"1252_CR3","unstructured":"Frax calculation tool. Osteoporosis Research https:\/\/www.fraxplus.org\/calculation-tool (2026)."},{"issue":"(suppl. 1)","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho, P. M. et al. American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis \u2014 2020 update. Endocr. Pract. 26 (suppl. 1), 1\u201346 (2020).","journal-title":"Endocr. Pract."},{"key":"1252_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","volume":"43","author":"PR Ebeling","year":"2022","unstructured":"Ebeling, P. R. et al. Secondary osteoporosis. Endocr. Rev. 43, 240\u2013313 (2022).","journal-title":"Endocr. Rev."},{"key":"1252_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11914-022-00717-y","volume":"20","author":"EM Lewiecki","year":"2022","unstructured":"Lewiecki, E. M. Evaluating patients for secondary causes of osteoporosis. Curr. Osteoporos. Rep. 20, 1\u201312 (2022).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1252_CR7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1530\/EJE-10-0015","volume":"162","author":"LC Hofbauer","year":"2010","unstructured":"Hofbauer, L. C., Hamann, C. & Ebeling, P. R. Approach to the patient with secondary osteoporosis. Eur. J. Endocrinol. 162, 1009\u20131020 (2010).","journal-title":"Eur. J. Endocrinol."},{"key":"1252_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.4158\/EP.12.4.436","volume":"12","author":"SE Painter","year":"2006","unstructured":"Painter, S. E., Kleerekoper, M. & Camacho, P. M. Secondary osteoporosis: a review of the recent evidence. Endocr. Pract. 12, 436\u2013445 (2006).","journal-title":"Endocr. Pract."},{"key":"1252_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s42000-023-00491-1","volume":"22","author":"E Anastasilaki","year":"2023","unstructured":"Anastasilaki, E., Paccou, J., Gkastaris, K. & Anastasilakis, A. D. Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management. Hormones 22, 611\u2013622 (2023).","journal-title":"Hormones"},{"key":"1252_CR10","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1111\/cts.13649","volume":"16","author":"BI Wallace","year":"2023","unstructured":"Wallace, B. I. et al. Prevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009\u20132018. Clin. Transl. Sci. 16, 2565\u20132576 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"1252_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/art.22294","volume":"56","author":"F De Vries","year":"2007","unstructured":"De Vries, F. et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 56, 208\u2013214 (2007).","journal-title":"Arthritis Rheum."},{"key":"1252_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa, T. P., Leufkens, H. G. & Cooper, C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777\u2013787 (2002).","journal-title":"Osteoporos. Int."},{"key":"1252_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Van Staa","year":"2000","unstructured":"Van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B. & Cooper, C. Use of oral corticosteroids and risk of fractures. J. Bone Min. Res. 15, 993\u20131000 (2000).","journal-title":"J. Bone Min. Res."},{"key":"1252_CR14","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi, P. et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 157, 107843 (2019).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1252_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2337\/dc22-1004","volume":"46","author":"AV Kvist","year":"2023","unstructured":"Kvist, A. V., Nasser, M. I., Vestergaard, P., Frost, M. & Burden, A. M. Site-specific fracture incidence rates among patients with type 1 diabetes, type 2 diabetes, or without diabetes in Denmark (1997\u20132017). Diabetes Care 46, 633\u2013642 (2023).","journal-title":"Diabetes Care"},{"key":"1252_CR16","doi-asserted-by":"publisher","first-page":"e1390","DOI":"10.1210\/clinem\/dgab882","volume":"107","author":"B Wang","year":"2022","unstructured":"Wang, B. et al. Unmasking fracture risk in type 2 diabetes: the association of longitudinal glycemic hemoglobin level and medications. J. Clin. Endocrinol. Metab. 107, e1390\u2013e1401 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1252_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01260-8","volume":"23","author":"X Liu","year":"2023","unstructured":"Liu, X., Chen, F., Liu, L. & Zhang, Q. Prevalence of osteoporosis in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies. BMC Endocr. Disord. 23, 1 (2023).","journal-title":"BMC Endocr. Disord."},{"key":"1252_CR18","doi-asserted-by":"publisher","first-page":"115457","DOI":"10.1016\/j.bone.2020.115457","volume":"137","author":"T Vilaca","year":"2020","unstructured":"Vilaca, T. et al. The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: a systematic review and meta-analysis update. Bone 137, 115457 (2020).","journal-title":"Bone"},{"key":"1252_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2337\/dc19-0925","volume":"43","author":"F Koromani","year":"2020","unstructured":"Koromani, F. et al. Vertebral fractures in individuals with type 2 diabetes: more than skeletal complications alone. Diabetes Care 43, 137\u2013144 (2020).","journal-title":"Diabetes Care"},{"key":"1252_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-8587(21)00347-8","volume":"10","author":"LC Hofbauer","year":"2022","unstructured":"Hofbauer, L. C. et al. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol. 10, 207\u2013220 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1252_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/YCO.0000000000000818","volume":"35","author":"Y Sil\u00e9n","year":"2022","unstructured":"Sil\u00e9n, Y. & Keski-Rahkonen, A. Worldwide prevalence of DSM-5 eating disorders among young people. Curr. Opin. Psychiatry 35, 362\u2013371 (2022).","journal-title":"Curr. Opin. Psychiatry"},{"key":"1252_CR22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/jbmr.4901","volume":"38","author":"M S\u00f8eby","year":"2023","unstructured":"S\u00f8eby, M., Gribsholt, S. B., Clausen, L. & Richelsen, B. Fracture risk in patients with anorexia nervosa over a 40-year period. J. Bone Min. Res. 38, 1586\u20131593 (2023).","journal-title":"J. Bone Min. Res."},{"key":"1252_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00223-021-00826-3","volume":"110","author":"C Hung","year":"2022","unstructured":"Hung, C., Mu\u00f1oz, M. & Shibli-Rahhal, A. Anorexia nervosa and osteoporosis. Calcif. Tissue Int. 110, 562\u2013575 (2022).","journal-title":"Calcif. Tissue Int."},{"key":"1252_CR24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/liv.13730","volume":"38","author":"N Gua\u00f1abens","year":"2018","unstructured":"Gua\u00f1abens, N. & Par\u00e9s, A. Osteoporosis in chronic liver disease. Liver Int. 38, 776\u2013785 (2018).","journal-title":"Liver Int."},{"key":"1252_CR25","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.chest.2019.06.036","volume":"156","author":"YW Chen","year":"2019","unstructured":"Chen, Y. W., Ramsook, A. H., Coxson, H. O., Bon, J. & Reid, W. D. Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis. Chest 156, 1092\u20131110 (2019).","journal-title":"Chest"},{"key":"1252_CR26","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s00198-017-4189-7","volume":"28","author":"K Briot","year":"2017","unstructured":"Briot, K., Geusens, P., Em Bultink, I., Lems, W. F. & Roux, C. Inflammatory diseases and bone fragility. Osteoporos. Int. 28, 3301\u20133314 (2017).","journal-title":"Osteoporos. Int."},{"key":"1252_CR27","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1007\/s00198-018-4586-6","volume":"29","author":"P Szafors","year":"2018","unstructured":"Szafors, P. et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos. Int. 29, 2389\u20132397 (2018).","journal-title":"Osteoporos. Int."},{"key":"1252_CR28","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1365-2362.2011.02545.x","volume":"41","author":"G Schett","year":"2011","unstructured":"Schett, G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur. J. Clin. Invest. 41, 1361\u20131366 (2011).","journal-title":"Eur. J. Clin. Invest."},{"key":"1252_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.coph.2018.03.006","volume":"40","author":"Y Tanaka","year":"2018","unstructured":"Tanaka, Y. & Ohira, T. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Curr. Opin. Pharmacol. 40, 110\u2013119 (2018).","journal-title":"Curr. Opin. Pharmacol."},{"key":"1252_CR30","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.3899\/jrheum.080356","volume":"35","author":"P Garnero","year":"2008","unstructured":"Garnero, P., Tabassi, N. C.-B. & Voorzanger-Rousselot, N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J. Rheumatol. 35, 2313\u20132315 (2008).","journal-title":"J. Rheumatol."},{"key":"1252_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/er.2015-1106","volume":"37","author":"JH Bassett","year":"2016","unstructured":"Bassett, J. H. & Williams, G. R. Role of thyroid hormones in skeletal development and bone maintenance. Endocr. Rev. 37, 135\u2013187 (2016).","journal-title":"Endocr. Rev."},{"key":"1252_CR32","doi-asserted-by":"publisher","first-page":"dgaa306","DOI":"10.1210\/clinem\/dgaa306","volume":"105","author":"J Pepe","year":"2020","unstructured":"Pepe, J. et al. Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF. J. Clin. Endocrinol. Metab. 105, dgaa306 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1252_CR33","doi-asserted-by":"publisher","first-page":"739","DOI":"10.20945\/2359-3997000000563","volume":"66","author":"L Bandeira","year":"2022","unstructured":"Bandeira, L., Silva, B. C. & Bilezikian, J. P. Male osteoporosis. Arch. Endocrinol. Metab. 66, 739\u2013747 (2022).","journal-title":"Arch. Endocrinol. Metab."},{"key":"1252_CR34","doi-asserted-by":"publisher","first-page":"101247","DOI":"10.1016\/j.beem.2018.09.013","volume":"38","author":"BC Silva","year":"2024","unstructured":"Silva, B. C., Cusano, N. E. & Bilezikian, J. P. Primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 38, 101247 (2024).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"1252_CR35","doi-asserted-by":"publisher","first-page":"1026028","DOI":"10.3389\/fmed.2022.1026028","volume":"9","author":"C Caffarelli","year":"2022","unstructured":"Caffarelli, C. et al. Bone fragility and sarcoidosis: an underestimated relationship. Front. Med. 9, 1026028 (2022).","journal-title":"Front. Med."},{"key":"1252_CR36","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2020.12.024","volume":"78","author":"M Pazianas","year":"2021","unstructured":"Pazianas, M. & Miller, P. D. Osteoporosis and chronic kidney disease-mineral and bone disorder (CKD-MBD): back to basics. Am. J. Kidney Dis. 78, 582\u2013589 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1252_CR37","doi-asserted-by":"publisher","first-page":"117108","DOI":"10.1016\/j.bone.2024.117108","volume":"184","author":"D Fitzpatrick","year":"2024","unstructured":"Fitzpatrick, D. et al. Secondary hyperparathyroidism: predictors and relationship with vitamin D status, bone turnover markers and bone mineral density. Bone 184, 117108 (2024).","journal-title":"Bone"},{"key":"1252_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41574-021-00555-5","volume":"17","author":"S Khosla","year":"2021","unstructured":"Khosla, S., Samakkarnthai, P., Monroe, D. G. & Farr, J. N. Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus. Nat. Rev. Endocrinol. 17, 685\u2013697 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1252_CR39","doi-asserted-by":"publisher","first-page":"116880","DOI":"10.1016\/j.bone.2023.116880","volume":"176","author":"B Wang","year":"2023","unstructured":"Wang, B. & Vashishth, D. Advanced glycation and glycoxidation end products in bone. Bone 176, 116880 (2023).","journal-title":"Bone"},{"key":"1252_CR40","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/jbmr\/zjaf094","volume":"40","author":"EM Curtis","year":"2025","unstructured":"Curtis, E. M. et al. Type 1 and 2 diabetes mellitus: comprehensive fracture risk relationships in UK Biobank. J. Bone Min. Res. 40, 1246\u20131254 (2025).","journal-title":"J. Bone Min. Res."},{"key":"1252_CR41","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00198-018-4650-2","volume":"29","author":"SL Ferrari","year":"2018","unstructured":"Ferrari, S. L. et al. Bone and Diabetes Working Group of IOF. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos. Int. 29, 2585\u20132596 (2018).","journal-title":"Osteoporos. Int."},{"key":"1252_CR42","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410\u2013427 (2021).","journal-title":"Lancet"},{"key":"1252_CR43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jbspin.2009.12.002","volume":"77","author":"B Bouvard","year":"2010","unstructured":"Bouvard, B. et al. Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis. Joint Bone Spine 77, 120\u2013124 (2010).","journal-title":"Joint Bone Spine"},{"key":"1252_CR44","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.jaip.2023.02.007","volume":"11","author":"TA Rama","year":"2023","unstructured":"Rama, T. A. et al. Bone and cytokine markers associated with bone disease in systemic mastocytosis. J. Allergy Clin. Immunol. Pract. 11, 1536\u20131547 (2023).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1252_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","volume":"67","author":"E van der Veer","year":"2012","unstructured":"van der Veer, E. et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67, 431\u2013438 (2012).","journal-title":"Allergy"},{"key":"1252_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf039","volume":"9","author":"S Cadiou","year":"2025","unstructured":"Cadiou, S. et al. Real-world efficacy and safety of burosumab in tumor-induced osteomalacia: case series from an early access program. JBMR Plus 9, ziaf039 (2025).","journal-title":"JBMR Plus"},{"key":"1252_CR47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","volume":"21","author":"D Haffner","year":"2025","unstructured":"Haffner, D. et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat. Rev. Nephrol. 21, 330\u2013354 (2025).","journal-title":"Nat. Rev. Nephrol."},{"key":"1252_CR48","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(24)00163-3","volume":"12","author":"J Paccou","year":"2024","unstructured":"Paccou, J. & Compston, J. E. Bone health in obesity before and after interventions to promote weight loss. Lancet Diabetes Endocrinol. 12, 748\u2013760 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1252_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/jbm4.10048","volume":"2","author":"C Gagnon","year":"2018","unstructured":"Gagnon, C. & Schafer, A. L. Bone health after bariatric surgery. JBMR Plus 2, 121\u2013133 (2018).","journal-title":"JBMR Plus"},{"key":"1252_CR50","doi-asserted-by":"publisher","first-page":"i3794","DOI":"10.1136\/bmj.i3794","volume":"354","author":"C Rousseau","year":"2016","unstructured":"Rousseau, C. et al. Change in fracture risk and fracture pattern after bariatric surgery: nested case\u2013control study. BMJ 354, i3794 (2016).","journal-title":"BMJ"},{"key":"1252_CR51","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00223-021-00815-6","volume":"110","author":"SA Hardcastle","year":"2022","unstructured":"Hardcastle, S. A. Pregnancy and lactation associated osteoporosis. Calcif. Tissue Int. 110, 531\u2013545 (2022).","journal-title":"Calcif. Tissue Int."},{"key":"1252_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-021-04776-7","volume":"22","author":"Y Qian","year":"2021","unstructured":"Qian, Y., Wang, L., Yu, L. & Huang, W. Pregnancy- and lactation-associated osteoporosis with vertebral fractures: a systematic review. BMC Musculoskelet. Disord. 22, 926 (2021).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1252_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-024-06520-0","volume":"24","author":"K Kasahara","year":"2024","unstructured":"Kasahara, K. et al. Pregnancy and lactation-associated osteoporosis as a major type of premenopausal osteoporosis: a retrospective cohort study based on real-world data. BMC Pregnancy Childbirth 24, 301 (2024).","journal-title":"BMC Pregnancy Childbirth"},{"key":"1252_CR54","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/jbmr.3750","volume":"34","author":"A Cohen","year":"2019","unstructured":"Cohen, A. et al. Women with pregnancy and lactation-associated osteoporosis (PLO) have low bone remodeling rates at the tissue level. J. Bone Min. Res. 34, 1552\u20131561 (2019).","journal-title":"J. Bone Min. Res."},{"key":"1252_CR55","doi-asserted-by":"publisher","first-page":"117744","DOI":"10.1016\/j.bone.2025.117744","volume":"204","author":"L Lynch","year":"2026","unstructured":"Lynch, L. et al. Genetic contributors to osteoporosis in pregnancy and lactation associated osteoporosis (PLO). Bone 204, 117744 (2026).","journal-title":"Bone"},{"key":"1252_CR56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","volume":"380","author":"K Barnett","year":"2012","unstructured":"Barnett, K. et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380, 37\u201343 (2012).","journal-title":"Lancet"},{"key":"1252_CR57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41572-022-00376-4","volume":"8","author":"ST Skou","year":"2022","unstructured":"Skou, S. T. et al. Multimorbidity. Nat. Rev. Dis. Primers 8, 48 (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1252_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-018-2060-4","volume":"19","author":"MT Puth","year":"2018","unstructured":"Puth, M. T., Klaschik, M., Schmid, M., Weckbecker, K. & M\u00fcnster, E. Prevalence and comorbidity of osteoporosis \u2014 a cross-sectional analysis on 10,660 adults aged 50 years and older in Germany. BMC Musculoskelet. Disord. 19, 144 (2018).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1252_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004142","volume":"20","author":"D Bliuc","year":"2023","unstructured":"Bliuc, D. et al. The association between multimorbidity and osteoporosis investigation and treatment in high-risk fracture patients in Australia: a prospective cohort study. PLoS Med. 20, e1004142 (2023).","journal-title":"PLoS Med."},{"key":"1252_CR60","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00198-017-4171-4","volume":"28","author":"NB Watts","year":"2017","unstructured":"Watts, N. B. Adverse bone effects of medications used to treat non-skeletal disorders. Osteoporos. Int. 28, 2741\u20132746 (2017).","journal-title":"Osteoporos. Int."},{"key":"1252_CR61","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein, R. S. Clinical practice. Glucocorticoid-induced bone disease. N. Engl. J. Med. 365, 62\u201370 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1252_CR62","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis, E., Mazziotti, G., Giustina, A. & Bilezikian, J. P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319\u20131328 (2007).","journal-title":"Osteoporos. Int."},{"key":"1252_CR63","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00198-015-3455-9","volume":"27","author":"MA Amiche","year":"2016","unstructured":"Amiche, M. A. et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos. Int. 27, 1709\u20131718 (2016).","journal-title":"Osteoporos. Int."},{"key":"1252_CR64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","volume":"61","author":"J Compston","year":"2018","unstructured":"Compston, J. Glucocorticoid-induced osteoporosis: an update. Endocrine 61, 7\u201316 (2018).","journal-title":"Endocrine"},{"key":"1252_CR65","doi-asserted-by":"publisher","first-page":"105604","DOI":"10.1016\/j.jbspin.2023.105604","volume":"90","author":"AD Anastasilakis","year":"2023","unstructured":"Anastasilakis, A. D., Naciu, A. M., Yavropoulou, M. P. & Paccou, J. Risk and management of osteoporosis due to inhaled, epidural, intra-articular or topical glucocorticoids. Joint Bone Spine 90, 105604 (2023).","journal-title":"Joint Bone Spine"},{"key":"1252_CR66","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/IJWH.S69907","volume":"7","author":"S Chumsri","year":"2015","unstructured":"Chumsri, S. Clinical utilities of aromatase inhibitors in breast cancer. Int. J. Womens Health 7, 493\u2013499 (2015).","journal-title":"Int. J. Womens Health"},{"key":"1252_CR67","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","volume":"26","author":"F Saad","year":"2008","unstructured":"Saad, F. et al. Cancer treatment-induced bone loss in breast and prostate cancer. J. Clin. Oncol. 26, 5465\u20135476 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1252_CR68","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell, R. et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J. Clin. Oncol. 26, 1051\u20131057 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1252_CR69","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner, T. D., Coleman, R., Hadji, P. & Hofbauer, L. C. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 6, 901\u2013910 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1252_CR70","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1210\/clinem\/dgab290","volume":"106","author":"EJ Ku","year":"2021","unstructured":"Ku, E. J. et al. Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 106, 3655\u20133667 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1252_CR71","doi-asserted-by":"publisher","first-page":"561","DOI":"10.7326\/0003-4819-134-7-200104030-00009","volume":"134","author":"DC Bauer","year":"2001","unstructured":"Bauer, D. C., Ettinger, B., Nevitt, M. C. & Stone, K. L. Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann. Intern. Med. 134, 561\u2013568 (2001).","journal-title":"Ann. Intern. Med."},{"key":"1252_CR72","doi-asserted-by":"publisher","first-page":"R158","DOI":"10.1530\/EC-20-0167","volume":"9","author":"A Brancatella","year":"2020","unstructured":"Brancatella, A. & Marcocci, C. TSH suppressive therapy and bone. Endocr. Connect. 9, R158\u2013R172 (2020).","journal-title":"Endocr. Connect."},{"key":"1252_CR73","doi-asserted-by":"publisher","first-page":"105714","DOI":"10.1016\/j.jbspin.2024.105714","volume":"91","author":"C Philippoteaux","year":"2024","unstructured":"Philippoteaux, C., Paccou, J., Chazard, E. & Cortet, B. Proton pump inhibitors, bone and phosphocalcic metabolism. Joint Bone Spine 91, 105714 (2024).","journal-title":"Joint Bone Spine"},{"key":"1252_CR74","doi-asserted-by":"publisher","first-page":"13501","DOI":"10.3390\/ijerph192013501","volume":"19","author":"TF da Maia","year":"2022","unstructured":"da Maia, T. F. et al. Increased risk of fractures and use of proton pump inhibitors in menopausal women: a systematic review and meta-analysis. Int. J. Environ. Res. Public Health 19, 13501 (2022).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"1252_CR75","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3904\/kjim.2018.331","volume":"35","author":"YW Min","year":"2020","unstructured":"Min, Y. W. et al. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study. Korean J. Intern. Med. 35, 1084\u20131093 (2020).","journal-title":"Korean J. Intern. Med."},{"key":"1252_CR76","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00223-018-0432-2","volume":"103","author":"JM Paik","year":"2018","unstructured":"Paik, J. M. et al. Proton pump inhibitor use, H2-receptor antagonist use, and risk of incident clinical vertebral fracture in women. Calcif. Tissue Int. 103, 380\u2013387 (2018).","journal-title":"Calcif. Tissue Int."},{"key":"1252_CR77","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00198-018-4788-y","volume":"30","author":"TN Poly","year":"2019","unstructured":"Poly, T. N., Islam, M. M., Yang, H. C., Wu, C. C. & Li, Y. J. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos. Int. 30, 103\u2013114 (2019).","journal-title":"Osteoporos. Int."},{"key":"1252_CR78","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00223-022-00946-4","volume":"110","author":"E Biver","year":"2022","unstructured":"Biver, E. Osteoporosis and HIV infection. Calcif. Tissue Int. 110, 624\u2013640 (2022).","journal-title":"Calcif. Tissue Int."},{"key":"1252_CR79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3851\/IMP3346","volume":"25","author":"B Baranek","year":"2020","unstructured":"Baranek, B., Wang, S., Cheung, A. M., Mishra, S. & Tan, D. H. The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis. Antivir. Ther. 25, 21\u201332 (2020).","journal-title":"Antivir. Ther."},{"key":"1252_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-00903-y","volume":"16","author":"CJ Chang","year":"2021","unstructured":"Chang, C. J., Chan, Y. L., Pramukti, I., Ko, N. Y. & Tai, T. W. People with HIV infection had lower bone mineral density and increased fracture risk: a meta-analysis. Arch. Osteoporos. 16, 47 (2021).","journal-title":"Arch. Osteoporos."},{"key":"1252_CR81","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman, F. et al. National Osteoporosis Foundation. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos. Int. 25, 2359\u20132381 (2014).","journal-title":"Osteoporos. Int."},{"key":"1252_CR82","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae146","volume":"191","author":"J Paccou","year":"2024","unstructured":"Paccou, J. et al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society. Eur. J. Endocrinol. 191, G1\u2013G17 (2024).","journal-title":"Eur. J. Endocrinol."},{"key":"1252_CR83","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey, M. B. et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 75, 2088\u20132102 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1252_CR84","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bone.2019.07.006","volume":"127","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis, A. D. et al. Bone disease following solid organ transplantation: a narrative review and recommendations for management from The European Calcified Tissue Society. Bone 127, 401\u2013418 (2019).","journal-title":"Bone"},{"key":"1252_CR85","doi-asserted-by":"publisher","first-page":"116236","DOI":"10.1016\/j.bone.2021.116236","volume":"154","author":"J Paccou","year":"2022","unstructured":"Paccou, J. et al. Bariatric surgery and skeletal health: a narrative review and position statement for management by the European Calcified Tissue Society (ECTS). Bone 154, 116236 (2022).","journal-title":"Bone"},{"key":"1252_CR86","doi-asserted-by":"publisher","first-page":"100694","DOI":"10.1016\/j.jbo.2025.100694","volume":"53","author":"P Hadji","year":"2025","unstructured":"Hadji, P. et al. Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: an updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J. Bone Oncol. 53, 100694 (2025).","journal-title":"J. Bone Oncol."},{"key":"1252_CR87","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jbspin.2018.09.017","volume":"86","author":"K Briot","year":"2019","unstructured":"Briot, K. et al. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. Joint Bone Spine 86, 21\u201328 (2019).","journal-title":"Joint Bone Spine"},{"key":"1252_CR88","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00198-025-07559-1","volume":"36","author":"CF Huang","year":"2025","unstructured":"Huang, C. F. et al. Asia\u2013Pacific consensus for the management of osteoporosis in men. Osteoporos. Int. 36, 1105\u20131114 (2025).","journal-title":"Osteoporos. Int."},{"key":"1252_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson, C. L. et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch. Osteoporos. 17, 58 (2022).","journal-title":"Arch. Osteoporos."},{"key":"1252_CR90","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. EHA Guidelines Committee; ESMO Guidelines Committee. Multiple myeloma: EHA-ESMO clinical practice. Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 309\u2013322 (2021).","journal-title":"Ann. Oncol."},{"key":"1252_CR91","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40618-023-02179-0","volume":"47","author":"MM Formosa","year":"2024","unstructured":"Formosa, M. M., Christou, M. A. & M\u00e4kitie, O. Bone fragility and osteoporosis in children and young adults. J. Endocrinol. Invest. 47, 285\u2013298 (2024).","journal-title":"J. Endocrinol. Invest."},{"key":"1252_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10791","volume":"7","author":"TJ Block","year":"2023","unstructured":"Block, T. J. et al. A novel RUNX1 genetic variant identified in a young male with severe osteoporosis. JBMR Plus 7, e10791 (2023).","journal-title":"JBMR Plus"},{"key":"1252_CR93","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/oby.24214","volume":"33","author":"S Gam","year":"2025","unstructured":"Gam, S. et al. Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo-controlled study. Obesity 33, 659\u2013670 (2025).","journal-title":"Obesity"},{"key":"1252_CR94","first-page":"A1069","volume":"39","author":"AL Schafer","year":"2024","unstructured":"Schafer, A. L. et al. Denosumab increases bone mass in postmenopausal women and older men undergoing bariatric surgery: a randomized controlled trial. J. Bone Mineral Res. 39, A1069 (2024).","journal-title":"J. Bone Mineral Res."},{"key":"1252_CR95","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas, K. et al. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J. Bone Oncol. 28, 100355 (2021).","journal-title":"J. Bone Oncol."},{"key":"1252_CR96","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant, M. et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386, 433\u2013443 (2015).","journal-title":"Lancet"},{"key":"1252_CR97","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG).","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386, 1353\u20131361 (2015).","journal-title":"Lancet"},{"key":"1252_CR98","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant, M. et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 339\u2013351 (2019).","journal-title":"Lancet Oncol."},{"key":"1252_CR99","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis, A. D. et al. Denosumab discontinuation and the rebound phenomenon: a narrative review. J. Clin. Med. 10, 152 (2021).","journal-title":"J. Clin. Med."},{"key":"1252_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10629","volume":"6","author":"M Wang","year":"2022","unstructured":"Wang, M., Wu, Y. F. & Girgis, C. M. Bisphosphonate drug holidays: evidence from clinical trials and real-world studies. JBMR Plus 6, e10629 (2022).","journal-title":"JBMR Plus"},{"key":"1252_CR101","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamapediatrics.2023.4588","volume":"177","author":"MATC van der Loos","year":"2023","unstructured":"van der Loos, M. A. T. C. et al. Bone mineral density in transgender adolescents treated with puberty suppression and subsequent gender-affirming hormones. JAMA Pediat. 177, 1332\u20131341 (2023).","journal-title":"JAMA Pediat."},{"key":"1252_CR102","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00198-025-07664-1","volume":"36","author":"L Karam","year":"2025","unstructured":"Karam, L., Mabilleau, G. & Paccou, J. Effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity. Osteoporos. Int. 36, 2115\u20132126 (2025).","journal-title":"Osteoporos. Int."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01252-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:01:02Z","timestamp":1784030462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01252-x","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"27 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}